A Phase 3 interventional study of Budesonide/Formoterol fumarate dihydrate in Asthma, sponsored by Franciscus Gasthuis. Recruiting at 1 site in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-25.
Sponsored by Franciscus Gasthuis · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 110 studies testing budesonide in Asthma — 6 open to participants now, 6 under way, 3 of them phase 3. Budesonide · Asthma.
Among the 110 studies testing budesonide in Asthma, this one is the 53rd largest by planned enrollment of the 108 interventional ones that give a count, is one of 2 that started in 2023, is one of 51 in phase 3, and was the 104th registered.
4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.
Browse Asthma studies →6 of the 110 studies testing budesonide in Asthma are open now, in 5 countries. Recruiting first, the newest first:
University of Miami · Sites in United States
Ages 18–75
Massachusetts General Hospital · Sites in United States
Ages 18–54
University of KwaZulu · Sites in South Africa
Ages 6–18
University of British Columbia · Sites in Canada
Ages 19–49
Hamad Medical Corporation · Sites in Qatar
Ages 2–14
By country, each count listing its studies:
Budesonide: first FDA approval 1994 (RHINOCORT), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 416 Asthma studies recruiting now, 141 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
110 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 6 · Phase 3 51 · Phase 4 33
First in 1991; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 138 is above the median of 79 across 3,346 interventional studies indexed under Asthma.
Median enrollment 124 across the 108 interventional studies. Of the 94 that completed or were terminated, 35 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
64 of 110 have an industry lead sponsor. The 10 most frequent:
Franciscus Gasthuis is the lead sponsor of 18 studies on the registry; 11 are open to participants now.
Franciscus Gasthuis has 3 studies filed under Asthma — fewer than ten, so there is no comparison to draw.
1 of the studies testing budesonide in Asthma that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07166939Massachusetts General Hospital45th Multicenter Airway Research Collaboration | 2027-06 |
Add it to your calendar (.ics) → With an account.
Among the 110 studies testing budesonide in Asthma, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The aim EXACT@Home is to create an evidence-based health program using e.g. questionnaires, a digital health platform and multiple digital devices to further improve the assessment of patients diagnosed with severe asthma. By better charting treatable traits (e.g. poor adherence, physical inactivity, dysfunctional breathing), we expect to improve the indication for the use of biologics. One the devices that will be used is also a medicinal product: a digital inhaler, which monitors adherence and inhaler technique through its connected application and aims to improve adherence and inhaler technique with reminders and notifications. Next to this an activity tracker, hand-held spirometer and FeNO measuring device will be used. The information of the devices will be collected in a Personal Digital Healthcare Environment (PDHE). Patients diagnosed with severe asthma according to the regional asthma Multi-Disciplinary Team Meeting (MDTM) eligible for a treatment with biologics will be included. Half of the patients will immediately receive a biologic. The other half will first undergo the systematic assessment including home monitoring (=EXACT@home) and afterwards a treatment will be chosen based on this evaluation: optimization of treatable traits when present and/or biologics. The chosen treatment of both, the intervention and control group, will be evaluated during 11-12 months.
Rationale:
Asthma is a common multifactorial disease with chronic inflammation of the lower airways, which is in most cases adequately treated by inhalation medication. 17% of asthma patients have difficult-to-treat asthma, which is uncontrolled despite of an optimal treatment with medication due to the presence of 'treatable traits'. Examples of treatable traits are poor adherence to ICS/LABA therapy and inhaler technique, dysfunctional breathing, physical inactivity and behavior. Severe and refractory asthma is a subtype of difficult-to-treat asthma and only occurs if the asthma is uncontrolled despite optimized treatment with medication and addressing of treatable traits, which occurs in only 3.7% of all asthma patients. This group of patients is responsible for a high burden of overall disease, as well as large healthcare costs.Treatment options with biologics have fundamentally changed the care for patients with severe asthma by giving a relevant improvement in asthma control, the number of asthma exacerbations and quality of life. On the other hand, these drugs are also very expensive and must be given for the correct indication.
The Centre of Excellence for severe Asthma, Franciscus Gasthuis \& Vlietland, Rotterdam organizes a weekly Multi-Disciplinary Team Meeting (MDTM) for hospitals in the South-West of the Netherlands to discuss their patients with problematic asthma and to start a treatment with biologics approved for severe asthma (in this document further called biologics). Despite maximal efforts of all stakeholders, the complete overview of a patient and the treatable traits is often hampered by the complexity and heterogeneity of severe asthma.
The aim of the EXACT@Home (Expertise Asthma COPD program with digital support) study is to further improve the assessment of treatable traits using ehealth before considering treatment with biologics.
Objectives:
Primary objective: To investigate if the EXACT@home program results in a reduced percentage of patients treated with biologics by means of systematically targeting treatable traits measured after 6 months of follow up.
Secondary objectives: To determine whether the use of EXACT@home results in a reduced percentage of patients treated with biologicals after 11-12 months. Next to this it will be investigated if EXACT@home has an influence on quality of life, asthma control, dyspnea perception, lung function, exacerbation frequency, prednisolone use, direct healthcare consumption, self-management skills, patient satisfaction, adherence to ICS/LABA therapy and inhaler technique, physical activity, sleep and vital parameters. Next to this, breath pattern analysis will be performed with the electronic nose (eNose). Moreover, the safety of the Digital inhaler (BF-Digihaler-DS from Teva) and eNose (Spironose from Breathomix) and the course of the treatment in each patient will also be investigated.
Study design:
Open-label, randomized controlled trial with a superiority design.
Study population:
Patients aged ≥ 18 years, in which the diagnosis severe and refractory asthma and eligibility for treatment with biologics was determined at the regional asthma MDTM will be asked to participate in this project.
Intervention (if applicable):
Patients will be randomized in 2 groups (intervention - and control group). The intervention group participates in a holistic assessment called EXACT@home consisting of a period of 6 weeks addressing diagnosis, asthma phenotype and treatable traits using e.g. questionnaires and digital devices measuring airway obstruction, eosinophilic airway inflammation, adherence to ICS/LABA therapy, inhalation technique, movement, vital parameters and sleep. The information of the devices and all other information concerning the patient will be stored in an 'Personal Digital Healthcare Environment (PDHE)'. Afterwards the collected data will be evaluated. Based on this evaluation and the degree of asthma control the type of treatment will be determined: optimization of 'treatable traits' or start of treatment with biologics. The control group will immediately start the treatment with biologics. The chosen treatment of both, the intervention and control group, will be evaluated during 11-12 months.
Main study parameters/endpoints:
Study parameter primary outcome:
Difference between the intervention and control group in the percentage of patients treated with biologicals after 6 months of follow up.
Study parameters secondary outcome:
The percentage of patients treated with biologicals after 11-12 months of follow up, quality of life, asthma control, dyspnea perception, lung function, exacerbation frequency, prednisolone use, direct healthcare consumption, self-management skills, patient satisfaction, adherence to ICS/LABA therapy, inhaler technique, physical activity, slap, vital parameters, breath pattern analysis with the eNose, safety of the digital inhaler and eNose and the course of the treatment in each patient.
Nature and extent of the burden and risks associated with participation, benefit and group relatedness:
The possible burden of the intervention group is temporarily postponing an effective treatment with biologics in favour of in depth extensive assessment in patients with a severe disease for a short period of at least 6 weeks. On the other hand, the patient could benefit from the EXACT@home assessment possibly leading to a personalized treatment, in which a treatment with biologics might not be necessary anymore. Next to this, another possible minor burden is 1 extra visit in addition to standard care.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
History of cancer:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
These patients will first undergo the systematic assessment (=EXACT@home) of +/- 6 weeks including a systematic anamnesis, questionnaires and home monitoring with multiple digital devices (digital inhaler, activity tracker, hand-held spirometer and FeNO measuring device) and a Personal Digital Health Environment (PDHE). Based on this evaluation and the degree of asthma control a treatment will be chosen: optimization of treatable traits if present and/or biologics. The personal digital healthcare environment and digital inhaler will be used for 12 months and the activity tracker, hand-held spirometer and FeNO measuring device will be used for 12 weeks.
Drug: Budesonide/Formoterol fumarate dihydrate
These patients will immediately receive a biologic after the indication is determined at the regional asthma Multi-Disciplinary Team Meeting (MDTM). These patients also have access to the Personal Digital Health Environment (PDHE) and they will also use the digital inhaler but without being able to see their own results or receiving feedback/reminders (silent). The personal digital healthcare environment and digital inhaler will be used for 12 months.
Drug: Budesonide/Formoterol fumarate dihydrate
Drug pages: BudesonideStudies of BudesonideBudesonide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · FormoterolStudies of FormoterolFormoterol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
The Digihaler will measure use of inhalation medication and inhaler technique and will give feedback and reminders. The aim is to improve adherence en inhaler technique. The device/medicinal product will be used for 12 months. It will be used in both groups, but patients in the intervention group are not able to see their own results and will not receive feedback/reminders.
Also known as: Budesonide Formoterol (BF) Digihaler Digital System (DS)
Difference in percentage of patients treated with biologicals after 6 months of follow up
Difference in number of patients who receive treatment with biologics in the intervention arm compared with the control arm
Time frame: 6 months
Difference in percentage of patients treated with biologicals after 12 months of follow up
Difference in number of patients who receive treatment with biologics in the intervention arm compared with the control arm
Time frame: 12 months
Difference in change in asthma control over time between the intervention- and control group
Asthma Controle assessed with the Asthma Control Questionnaire (ACQ-5). This questionnaire consists of five questions about the severity of symptoms which a patient experieces. The score range per question is 0-7 (0 = never and 7 = always). The total score will be calculated by dividing the sum of all scores by the amount of questions. A higher score is associated with worse asthma control.
Time frame: 6-12 months
Difference in change in quality of life over time between the intervention- and control group
Disease specific quality of life is measured with the Asthma Quality of Life Questionnaire (mini AQLQ). The mini AQLQ consists of 15 questions, which are subdivided into 4 domains (symptoms, activity limitation, emotional function and environmental stimuli). Each question has a 7-point scale (7 = not impaired at all - 1 = severely impaired). The overall score is the mean of all 15 responses. A lower score corresponds to a better quality of life.
Time frame: 6-12 months
Difference in asthma exacerbation frequency
Asthma exacerbation frequency
Time frame: 6-12 months
Difference in change in spirometry and FeNO over time between the intervention - and control group.
Spirometry (e.g. FEV1, FVC) and FeNO measurements
Time frame: 6-12 months
Difference in direct healthcare consumption between the intervention- and control group
A Health Care Resource Utilization analysis will be performed by measuring the number of hospitalizations, the duration of hospitalization, the number of unscheduled visits to a health care provider (such as visits to the emergency department, general practitioner and outpatient clinic) all related to asthma and asthma exacerbations for which prednisolone with or without antibiotics was needed. This together with the cost of asthma biologics and equipment, staff and logistics for implementation and evaluation of EXACT@home.
Time frame: 6-12 months
Difference in prednisolone courses between the intervention- and control group.
Number of prednisolon courses
Time frame: 6-12 months
Difference in reduction in prednisolone maintenance therapy (if applicable) between the intervention and control group
Reduction in prednisolon maintenace therapy between the intervention- and control group. Reduction is defined as a decrease in prednisolon maintance therapy of ≥ 5 mg.
Time frame: 6-12 months
Difference in cumulative prednisolon dosage between the intervention- and control group.
Cumulative prednisolon dosage. The cumulative prednisolon dosage is the total amount of prednisolon a patient recieved during the year the patient participated in the study. The is calculated with prednisolone maintance therapy and prednisolone courses.
Time frame: 6-12 months
Difference in self-management between the intervention- and control group.
Knowledge, skills and confidence in being able to manage one's own health or illness: Patient Activation Measure (PAM). PAM is a questionnaire that measures knowledge, skills and trust in the ability to manage health or disease. The aim of PAM is to gain insight in the ability of the patient to improve their health status. It contains 13 questions that are rated on a 5-point scale. Based on the total score patients are scored along 4 levels: from very passive, not able to take control of their disease (PAM 1) towards active patients that feel completely in control of their disease (PAM 4).
Time frame: 6-12 months
Difference in dyspnea perception between the intervention- and control group.
Dyspnea perception is measured with the modified Medical Research Council (mMRC) dyspnea questionnaire. The MCR is a dyspnea scale, as a measure of disability in patients with respiratory disabilities. It consists of one question about shortness of breath and six possible answers. The score range 0 to 4 (0 = no shortness of breath at all and 4 = too breathless to leave the house or breathless with dressing/undressing). A higher score is therefore associated with a high burden of disease.
Time frame: 6-12 months
Difference in wellbeing between the intervention- and control group
Wellbeing is measured with the Wellbeing Of Older People (WOOP) questionnaire. The WOOP is a questionnaire which captures aspects relevant to the well-being of people. It consists of 9 questions. The scoring range for each question is from 1 to 5 (1 = no problems - 5 = very serious problems). The item scores will be summed to calculated the total score, which can range from 9 to 45, with higher scores indicating higher well-being.
Time frame: 6-12 months
Difference in patient satisfaction between the intervention- and control group
Patient satisfaction is measured with the Patients Assessment Chronic Illness Care (PACIC) questionnaire. The PACIC questionnaire measures specific actions or qualities of care, that patients report they have experienced in the delivery system. The survey includes 20 items, each with a score from 1 to 5 (1 = none of the time - 5 = always). The overall score is the mean of all 20 scores. The 20 items can also be divided into 5 subscales of which the mean can be calculated per subscale.
Time frame: 6-12 months
Measuring the change over time in physical activity in the intervention group
Physical activity (e.g. steps, percentage activity type) is measured with two activity trackers: the DynaPort Movemonitor from McRoberts and the Cardiowatch from Corsano.
Time frame: 6-12 months
Measuring the change over time in adherence and inhaler technique in the intervention group and the control group seperately
Adherence and inhaler technique are measured with the BF-Digihaler-DS, a digital inhaler which measures the moment of inhalation and inspiratory flow. Adherence is also measured with the Test of Adherence to Inhalers (TAI) questionnaire. TAI is a questionnaire which identifies patients with low adherence, determines the degree of adherence and gives an idea of the type or pattern of non-compliance. The TAI-10 consists of 10 questions and identifies patients with poor adherence and their degree of adherence. The scoring for each question ranges from 1 to 5 (1 = worst compliance - 5 = best compliance). All items provide a total score of between 10 (minimum) and 50 (maximum). A higher score is related to better adherence.
Time frame: 6-12 months
Observing sleeping patterns in the intervention group
Sleep is measured with the Cardiowatch from Corsano.
Time frame: 6-12 months
Observing vital parameters in the intervention group.
Vital parameters consists of the heart rate, respiratory rate, temperature. These are measured with the Cardiowatch from Corsano.
Time frame: 6-12 months
Measuring the differences in VOCs in exhaled breath measured with the eNose between baseline and follow-up in the intervention and in the control group separately.
VOCs in exhaled breath are measured with the Electronic Nose (eNose) from Breathomics
Time frame: 6-12 months
Monitoring of safety of the Digital inhaler (BF-Digihaler-DS from Teva) and eNose (Spironose from Breathomix).
Safety is measured by reporting adverse (device) events.
Time frame: 6-12 months
Monitoring and recording the course of treatment of each patient including the explanation behind changes in treatment (e.g. stopping treatment with biologicals).
The course of the treatment is documented for each patient.
Time frame: 6-12 months
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2023 (actual). Primary completion is estimated for Apr 2025, 26 months after the start.
Of 32 non-industry phase 3 interventional studies under Asthma, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 54. This study's planned 26 months is below that.
Counting every sponsor, half of 205 studies reached it within 27 months; a quarter within 14 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Budesonide · Formoterol
Franciscus Gasthuis